|
Silymarin,
cirrhosis and diabetes: an abstract
by THanbey (WebMD), on 12/30/2001 6:53:58 PM
Long-term (12 months) treatment with an anti-oxidant drug (silymarin)
is effective on hyperinsulinemia, exogenous insulin need and
malondialdehyde levels in cirrhotic diabetic patients
Velussi M, Cernigoi AM, De Monte A, Dapas F, Caffau C, Zilli M
Anti-Diabetes Centre, Monfalcone Hospital, Gorizia, Italy. J
Hepatol 1997 Apr;26(4):871-9
Background/Aims: Several studies have demonstrated that
diabetic patients with cirrhosis require insulin treatment
because of insulin resistance. As chronic alcoholic liver
damage is partly due to the lipoperoxidation of hepatic cell
membranes, anti-oxidizing agents may be useful in treating or
preventing damage due to free radicals. The aim of this study
was to ascertain whether long-term treatment with silymarin is
effective in reducing lipoperoxidation and insulin resistance
in diabetic patients with cirrhosis.
Methods: A 12-month open, controlled study was conducted in
two well-matched groups of insulin-treated diabetics with
alcoholic cirrhosis. One group (n = 30) received 600 mg
silymarin per day plus standard therapy, while the control
group (n = 30) received standard therapy alone. The efficacy
parameters, measured regularly during the study, included
fasting blood glucose levels, mean daily blood glucose levels,
daily glucosuria levels, glycosylated hemoglobin (HbA1c) and
malondialdehyde levels.
Results: There was a significant decrease (p < 0.01) in
fasting blood glucose levels, mean daily blood glucose levels,
daily glucosuria and HbA1c levels already after 4 months of
treatment in the silymarin group. In addition, there was a
significant decrease (p < 0.01) in fasting insulin levels
and mean exogenous insulin requirements in the treated group,
while the untreated group showed a significant increase (p
< 0.05) in fasting insulin levels and a stabilized insulin
need. These findings are consistent with the significant
decrease (p < 0.01) in basal and glucagon-stimulated
C-peptide levels in the treated group and the significant
increase in both parameters in the control group. Another
interesting finding was the significant decrease (p < 0.01)
in malondialdehyde/levels observed in the treated group.
Conclusions: These results show that treatment with silymarin
may reduce the lipoperoxidation of cell membranes and insulin
resistance, significantly decreasing endogenous insulin
overproduction and the need for exogenous insulin
administration.
|